11:43 AM EST, 11/05/2025 (MT Newswires) -- All three major US stock indexes were up in late-morning trading Wednesday, as some big artificial-intelligence companies saw share gains after experiencing losses the day prior.

In company news, McDonald's (MCD) reported Q3 non-GAAP earnings Wednesday of $3.22 per diluted share, down from $3.23 a year earlier and below the FactSet consensus analyst expectation of $3.33. Third-quarter revenue was $7.08 billion, up from $6.87 billion a year ago and matching the FactSet consensus. Global same-store sales growth was 3.6%, compared to a 1.5% decline a year earlier and the FactSet consensus of 3.5% growth. McDonald's shares were up 2% around midday.

Advanced Micro Devices ( AMD ) reported Q3 adjusted earnings late Tuesday of $1.20 per diluted share, up from $0.92 a year earlier and above the FactSet consensus of $1.17. Third-quarter revenue was $9.25 billion, up from $6.82 billion a year ago and above the FactSet consensus of $8.76 billion. For Q4, the company expects revenue of $9.60 billion, plus or minus $300 million, compared to the FactSet consensus of $9.21 billion. AMD shares were up 0.8%.

Novo Nordisk ( NVO ) reported Q3 earnings Wednesday of 4.50 Danish kroner ($0.69) per diluted share, down from 6.12 kroner a year earlier and below the FactSet consensus of 4.90 kroner. Third-quarter revenue was 74.98 billion kroner, up from 71.31 billion kroner a year ago but below the FactSet consensus of 76.49 billion kroner. For full-year 2025, the company said it expects sales growth of 8% to 11% at constant exchange rates, compared to its previous guidance of 8% to 14%. Novo Nordisk ( NVO ) said it has accepted the US Inflation Reduction Act's Maximum Fair Price for its semaglutide-based Ozempic, Rybelsus and Wegovy products in Medicare Part D. The prices will go into effect in January 2027, the company said. Novo Nordisk ( NVO ) shares were down 3.8%.

Trex (TREX) reported Q3 adjusted earnings late Tuesday of $0.51 per diluted share, up from $0.37 a year earlier but below the FactSet consensus of $0.57. Third-quarter net sales were $285.3 million, up from $233.7 million a year ago but below the FactSet consensus of $301.7 million. For Q4, the company expects sales of $140 million to $150 million, below the FactSet consensus of $199 million. For full-year 2025, Trex expects revenue of $1.15 billion to $1.16 billion, below the FactSet consensus of $1.23 billion. Trex shares were down past 28%.

Teva Pharmaceutical Industries ( TEVA ) reported Q3 non-GAAP earnings Wednesday of $0.78 per diluted share, up from $0.69 a year earlier and above the FactSet consensus of $0.68. Third-quarter net revenue was $4.48 billion, up from $4.33 billion a year ago and above the FactSet consensus of $4.34 billion. For full-year 2025, the company said it expects non-GAAP EPS of $2.55 to $2.65, compared to the previous guidance of $2.50 to $2.65 and the FactSet consensus of $2.57. Full-year revenue is expected to be $16.8 billion to $17 billion, compared to its previous projection of $16.8 billion to $17.2 billion and the FactSet consensus of $16.83 billion. Teva shares were up more than 21%.

Price: 304.52, Change: +5.31, Percent Change: +1.77